Cartherics and TiCARos collaborate to lead advancement of CLIP-CAR technology

Cartherics, a leading allogenic NK cell platform developer, has announced a collaboration with TiCARos to develop CAR-NK products for cancer treatment. The partnership will utilize TiCARos’ CLIP-CAR technology to create CLIP-CAR constructs that will be incorporated into Cartherics’ NK cells for in vitro and in vivo assessments of their function.

TiCARos specializes in developing CAR-T cell products for the treatment of solid and blood cancers using its unique CLIP-CAR approach. This approach stabilizes the immune synapse between immune cells and tumor cells, resulting in improved efficacy in models. By combining TiCARos’ technology with Cartherics’ allogenic NK cell platform, the collaboration aims to enhance the effectiveness of cancer therapies.

Cartherics’ CEO, Professor Alan Trounson, believes that this partnership has the potential to build a leading portfolio of therapeutic products for cancer treatment. The two companies are focusing on targeting tissue factor (TF) for triple negative breast cancer and other challenging cancers. Each company has nominated a specific tumor antigen to target with CARs; Cartherics is targeting TF while TiCARos is targeting CD19.

The collaboration aims to accelerate pipeline programs and expand the use of TiCARos’ technology beyond autologous cell therapies. If the research collaboration yields positive results, Cartherics and TiCARos will negotiate a development and commercialization agreement for their CAR-NK therapeutic approach.

Overall, this partnership between two innovative companies has the potential to revolutionize cancer treatment by developing more effective CAR-NK products that can be used both in vitro and in vivo.

By Samantha Johnson

As a content writer at, I craft engaging and informative articles that aim to captivate readers and provide them with valuable insights. With a background in journalism and a passion for storytelling, I thoroughly enjoy delving into diverse topics, conducting research, and producing compelling content that resonates with our audience. From breaking news pieces to in-depth features, I strive to deliver content that is both accurate and engaging, constantly seeking to bring fresh perspectives to our readers. Collaborating with a talented team of editors and journalists, I am committed to maintaining the high standards of journalism upheld by our publication.

Leave a Reply